explore -WSS

explore

author：focus 2025-09-06 03:50:31 - browse：522

Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT — Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： J&J to buy cancer drug developer Ambrx Biopharma

focus

WSS

Federal weight loss drug coverage is 30 years out of date

ADCs take center stage as promising cancer treatments

UnitedHealth, Optum discontinue NaviHealth name

A single drug, study failures leave Anavex with nothing but cash

The biotech scorecard for Q1: 17 stock

AdventHealth escalates lawsuit against insurance vendor Multiplan

entertainment

explore

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Videos point to link between seizures and unexplained toddler deaths

United colonoscopy coverage change 'may cost lives,' doctors say

Burning questions for the 2024 JPM Healthcare Conference

Jerome Adams on the need for new antivirals for Covid

How AI can help patients find reliable information about doctors

Activists slam private health insurers over coverage restrictions

Why psychiatrists like me stop taking insurance

At least 13 dead in Texas as scorching temps continue

CZI to create biohub to build anti

hotspot

How a scoliosis diagnosis changed the life of one young dancer

Questions loom on AstraZeneca cancer drug as safety concerns ebb

U.K. sequencing study surfaces new findings about tumor DNA

Questions loom on AstraZeneca cancer drug as safety concerns ebb

How a scoliosis diagnosis changed the life of one young dancer

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Wikipedia

focus

leisure time

focus